

Basic science

Kv1.3 blockade by ShK186 modulates CD4⁺ effector memory T-cell activity of patients with granulomatosis with polyangiitis

Lucas L. Lintermans¹, Coen A. Stegeman², Ernesto J. Muñoz-Elías³, Eric J. Tarcha⁴, Shawn P. Iadonato⁴, Abraham Rutgers¹, Peter Heeringa⁵, Wayer H. Abdulahad⁵ ^{1,5*}

¹Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

²Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

³Prometheus Biosciences, San Diego, CA, USA

⁴Kineta Inc, Seattle, WA, USA

⁵Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

*Correspondence to: Wayer H. Abdulahad, Department of Rheumatology and Clinical Immunology, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzplein 1, 9713GZ Groningen, The Netherlands. E-mail: w.abdulahad@umcg.nl

Abstract


Objectives: Granulomatosis with polyangiitis (GPA) is a chronic relapsing systemic autoimmune vasculitis. Current treatment of GPA is unsatisfactory, as it relies on strong immunosuppressive regimens, with either CYC or rituximab, which reduce the immunogenicity of several vaccines and are risk factors for a severe form of COVID-19. This emphasizes the need to identify new drug targets and to develop treatment strategies with less harmful side effects. Since CD4⁺ effector memory T cells (T_{EM}) play a key role in the pathogenesis of GPA, we aimed in this study to modulate CD4⁺T_{EM} cell activity via Kv1.3 blockade using the specific peptide inhibitor, ShK-186.

Methods: Peripheral blood samples from 27 patients with GPA in remission and 16 age- and sex-matched healthy controls (HCs) were pre-incubated *in vitro* in the presence or absence of ShK-186, followed by stimulation with phorbol myristate acetate, calcium ionophore and brefeldin-A. The effect of ShK-186 on the cytokine production (IFN γ , TNF α , IL-4, IL-17, IL-21) within total and subsets of CD4⁺ T helper (CD4⁺T_H) cells were assessed using flow cytometry.

Results: ShK-186 reduced the expression level of IFN γ , TNF α , IL-4, IL-17 and IL-21 in CD4⁺T_H cells from patients with GPA *in vitro*. Further analysis performed on sorted CD4⁺T cell subsets, revealed that ShK-186 predominantly inhibited the cytokine production of CD4⁺T_{EM} cells. ShK-186 treatment reduced the production of the pro-inflammatory cytokines to the level seen in CD4⁺T_H cells from HCs.

Conclusions: Modulation of cellular effector function by ShK-186 may constitute a novel treatment strategy for GPA with high specificity and less harmful side effects.

Graphical abstract



Received: 10 October 2022. Accepted: 18 April 2023

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Keywords: granulomatosis with polyangiitis, ANCA, T cells, cytokines, Kv1.3 potassium channels

Rheumatology key messages

- ShK-186 treatment normalized the production of the pro-inflammatory cytokines in CD4⁺ T helper (CD4⁺T_H) cells from patients with GPA.
- ShK-186 predominantly affects the cytokine production of CD4⁺ effector memory T cells (CD4⁺T_{EM}) cells without impairing other CD4⁺ T cell subsets.
- Selective targeting of CD4⁺T_{EM} cells by ShK-186 might have value in the treatment of patients with GPA.

Introduction

Granulomatosis with polyangiitis (GPA) is the prototype of ANCA-associated vasculitis (AAV). It is a chronic relapsing systemic autoimmune disease characterized by medium- to small-sized vessel vasculitis predominantly affecting the upper and lower respiratory tract and kidneys, which may result in life-threatening complications [1, 2]. Current treatment consists of non-specific immunosuppressive therapy, including CYC in combination with CSs [3–5]. More recently, B cell depletion therapy with rituximab has been demonstrated to be equally effective as conventional therapy in inducing disease remission [6]. Unfortunately, these immunosuppressive drugs, rituximab in particular, also reduce the immunogenicity of several vaccines and are risk factors for a severe form of COVID-19, emphasizing the need to identify novel molecular targets to develop more selective and less harmful treatment strategies [7–9].

It remains unknown how GPA develops, but accumulating evidence indicates a key role for CD4⁺ effector memory T cells (T_{EM}) and their inflammatory cytokines [such as IL-17, IL-21 and IFN-gamma (IFN γ)] in the induction and progression of GPA [10–15]. Therefore, selective targeting of CD4⁺T_{EM} cells without impairing other arms of cellular immunity might have value in the treatment of patients with GPA.

CD4⁺T_{EM} cells preferentially rely on the voltage-gated potassium Kv1.3 channels to maintain their activation and effector function [16, 17]. It has been shown that Kv1.3 channels are highly expressed on CD4⁺T_{EM} cells (~1500 channels per cell), whereas naïve (CD4⁺T_{NAIVE}) and central memory (CD4⁺T_{CM}) CD4⁺T cells express lower levels of Kv1.3 channels (~250 channels per cell) [17]. CD4⁺T_{EM} cells use the Kv1.3 channels to regulate Ca²⁺ signalling by controlling the membrane potential. During activation, intracellular Ca²⁺ stores are released, leading to a depletion of these stores and an influx of extracellular Ca²⁺. This influx is maintained by the release of K⁺ through Kv1.3 channels, which helps sustain the elevated levels of Ca²⁺ required for optimal T_{EM} cell activation. Blocking Kv1.3 channels can inhibit this process by preventing the release of K⁺, leading to a decrease in Ca²⁺ influx and subsequently inhibiting T_{EM} cell activation [16]. Therefore, Kv1.3 channels may serve as an attractive target for specific immunomodulation in T_{EM} cell-mediated chronic or autoimmune diseases. Kv1.3 channels can be selectively inhibited by synthetic analogues of a native ShK toxin isolated from the sea anemone *Stichodactyla helianthus*. Previous studies have demonstrated that blocking of Kv1.3 channels by ShK analogues ameliorates disease development in animal

models of multiple sclerosis (MS), RA, type 1 diabetes mellitus (T1DM) and contact dermatitis, without compromising protective immune responses to acute infections [18–20]. In particular, ShK-186, a 37-amino acid synthetic analogue of ShK, has shown promising long-lasting therapeutic potential in animal models of autoimmunity, due to its high selectivity and tight binding to and slow release from the Kv1.3 channels on T cells [21]. Accordingly, we hypothesized that selective blocking of Kv1.3 channels on CD4⁺ T_{EM} cells from patients with GPA, using a highly potent ShK-186 peptide, reduce their pathogenic activity through modulating their pro-inflammatory cytokine production. Selective targeting of CD4⁺T_{EM} cells without impairing other arms of cellular immunity might have value in the treatment of GPA.

Materials and methods

Study population

Twenty-seven patients with GPA in remission and 16 age-matched healthy controls (HCs) [5 males and 11 females, mean age of 60 years, range (27–77)] were included in this study. The diagnosis of GPA was established according to the definition of the Chapel Hill Consensus Conference and fulfilled the classification of the ACR [22]. Only patients with GPA without clinical signs and symptoms of active disease and considered to have complete remission of their disease, as indicated by a BVAS of 0, were included in this study [23]. All patients were PR3-ANCA positive at disease diagnosis, and 20 patients had biopsy-proven vasculitis. At the time of sampling, 18 patients were PR3-ANCA positive, as indicated by an ANCA titre of $\geq 1:40$. The PR3-ANCA titres were measured by IIF on ethanol-fixed human granulocytes according to the standard procedure as described previously [24]. Twenty-one patients were considered to have generalized disease, and six patients were considered to have localized disease, in which the disease was confined to the upper and lower respiratory tract. None of the patients experienced an infection at the time of sampling, as indicated by a median CRP level of 5.8 mg/l. Eight of the 27 patients with GPA were treated with maintenance immunosuppressive therapy at the time of blood withdrawal. One patient with GPA received AZA, five patients with GPA received AZA in combination with prednisolone, and two patients with GPA were treated with low-dose prednisolone. Detailed clinical and laboratory characteristics of the patients are summarized in Table 1. All patients and healthy controls provided informed consent, and the local medical ethics committee of the University Medical Center Groningen approved the study.

Table 1. Clinical and laboratory characteristics of the patients with GPA at the time of blood sampling

	GPA
Subjects, <i>n</i> (% male)	27 (44%)
Age, mean (range)	61 (34–79)
PR3-ANCA positive ^a , <i>n</i> (% positive)	18 (67%)
Localized/generalized disease, <i>n</i> (% generalized)	6/21 (78%)
CRP (mg/l), median (range)	5.8 (<0.3–11)
eGFR ^b ml/min/1.73 m ² , median (range)	64 (15–91)
Disease duration in years, median (range)	9.5 (1.3–30.8)
Number of previous relapses, median (range)	1 (0–6)
Non/maintenance immunosuppressive therapy ^c , <i>n</i>	19/8

^a ANCA-positive titre $\geq 1:40$, ANCA-negative $\leq 1:20$.

^b Estimated Glomerular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

^c Immunosuppressive maintenance therapy: AZA, AZA + prednisolone, or prednisolone.

Sample preparation and *in vitro* peripheral blood stimulation

Lithium-heparinized venous blood was obtained from patients with GPA and HCs. Immediately after blood withdrawal, 2 ml of blood was mixed with 2 ml of Roswell Park Memorial Institute (RPMI) 1640 medium (Lonza, Basel, Switzerland), supplemented with 50 µg/ml Gentamicin (GIBCO, Life Technologies, Grand Island, NY, USA) and 10% foetal calf serum. The diluted blood samples were aliquoted into 5 ml polypropylene tubes (Falcon[®], Corning incorporated) at 400 µl per tube. Next, the blood samples were pre-incubated in the presence or absence of ShK-186 [dose range (0.1–100 nM); Kineta Inc, Seattle, WA, USA] for 1 h at 37°C, followed by stimulation with 50 ng/ml phorbol myristate acetate (PMA; Sigma-Aldrich, St Louis, MO, USA) and 2 mM calcium ionophore (CaI, Sigma-Aldrich). The cultures were incubated for 16 h at 37°C with 5% CO₂. As a negative control, one sample was kept without stimulation. To inhibit cytokine release from cells, 10 µg/ml brefeldin A (BFA; Sigma-Aldrich) was added to each sample.

IF staining of peripheral blood

After stimulation of the peripheral blood, erythrocytes were lysed using ammonium chloride, and the cells were washed in wash buffer [PBS containing 1% (w/v) BSA]. The T cells were stained with Brilliant Violet 605-conjugated anti-CD3 (Biolegend, San Diego, CA, USA), APC-eF780-conjugated anti-CD8 (eBioscience, San Diego, CA, USA), FITC-conjugated CD45RO (BD Pharmingen[™], Franklin Lakes, NJ, USA) and PE-Cy7-conjugated CCR7 (BD Pharmingen[™]) for 15 min at room temperature. The cells were fixed with 100 µl fixation reagent A (Fix/Perm medium A, Thermo Fisher Scientific) for 15 min. After washing, the cells were resuspended in 100 µl permeabilization reagent B (Fix/Perm medium B, Thermo Fisher Scientific) and labelled with PerCP-Cy5.5-conjugated anti-IL-4 (Biolegend), APC-conjugated anti-IL-17A (eBioscience), PE-conjugated anti-IL-21 (eBioscience), Alexa Fluor[®]700-conjugated anti-IFN γ (BD Pharmingen[™]) and Pacific Blue-conjugated anti-TNF α (Biolegend) for 30 min at room temperature in the dark. Finally, the samples were washed and analysed by nine-colour flow cytometric analyses on BD[™] LSR II flow cytometer. Data were collected for 5×10^5 events for each sample and plotted using Kaluza v1.5a (Beckman Coulter, Brea, CA, USA). Because stimulation reduces the surface expression of

CD4 on T cells, CD4⁺T cells were identified indirectly by gating CD3-positive and CD8-negative lymphocytes. Gated CD4⁺T cells were further displayed as density dot plots for the evaluation of intracellular cytokine production. The unstimulated negative control sample was used to discriminate cytokine-producing from non-cytokine-producing CD4⁺T cell populations.

Isolation of CD4⁺T_{NAIVE} and CD4⁺T_{EM} cells

Peripheral blood mononuclear cells (PBMCs) of 5 HCs were used for cell sorting experiments. Cell suspensions were stained for CD3, CD8, CD45RO and CCR7. CD4⁺T cells were gated negatively as CD3-positive and CD8-negative cells and sorted into: CD4⁺T_{NAIVE} (CD45RO⁻CCR7⁺), CD4⁺T_{CM} (CD45RO⁺CCR7⁺), CD4⁺T_{EM} (CD45RO⁺CCR7⁻) and CD4⁺T_{TD} (CD45RO⁻CCR7⁻) cell fractions on a MoFLO Astrios sorter (Beckman Coulter). The purity of the sorted CD4⁺T cell subsets, as determined by a post sort analysis, was >98% for all sorted CD4⁺T cell subsets. From each subset, 2.5×10^5 cells were incubated in the presence or absence of ShK-186 [dose range (0.1–100 nM); Kineta Inc] for 1 h at 37°C, followed by stimulation with 50 ng/ml PMA (Sigma-Aldrich) and 2 mM CaI (Sigma-Aldrich) in the presence of BFA. Following incubation for 16 h at 37°C with 5% CO₂, the cells were washed, premeabilized, and stained intracellularly for IL-4 (Biolegend), IL-17A, IL-21 (eBioscience), IFN γ (BD Pharmingen[™]) and TNF α (Biolegend). Finally, the samples were acquired on a BD[™] LSR II flow cytometer (BD Biosciences), and the data was analysed using Kaluza 1.5a. Unstimulated samples were used as a negative control for setting gates to define cytokine-producing cells.

Statistical analysis

Statistical analysis was performed using GraphPad prism (GraphPad Software, San Diego, CA, USA). Data are presented as median values or mean \pm SEM, as indicated. Data were analysed with the D'Agostino & Pearson omnibus normality test for Gaussian distribution. For comparison between patients with GPA and HCs, the unpaired *t* test was used for data with Gaussian distribution and the Mann–Whitney *U* test for data without Gaussian distribution. For intra-individual comparison between samples treated with or without ShK-186, the paired *t* test was used for data with Gaussian distribution and the Wilcoxon signed rank test for data without Gaussian distribution. Differences were considered statistically significant for 2-sided *P*-values ≤ 0.05 .

Results

T cell subset distribution in peripheral blood of patients with GPA in remission

We first assessed the distribution of CD4⁺T cell subsets in the peripheral blood of patients with GPA in remission and HCs. CD4⁺T cell subsets were identified based on the surface expression of CD45RO and CCR7 and divided into CD4⁺T_{NAIVE} cells (CD45RO⁻CCR7⁺), CD4⁺T_{CM} (CD45RO⁺CCR7⁺), CD4⁺T_{EM} cells (CD45RO⁺CCR7⁻) and CD4⁺terminal differentiated cells (T_{TD}, CD45RO⁻CCR7⁻) (Fig. 1A). We found that the percentage of circulating CD4⁺T_{EM} cells in patients with GPA was significantly higher compared with that in HCs (Fig. 1B), and the percentage of circulating CD4⁺T_{NAIVE} cells was significantly lower in patients with GPA compared with that in HCs, whereas the




Figure 1. Increased percentage of circulating CD4⁺ T_{EM} cells in patients with GPA. **(A)** Representative flow cytometry dot plots of CD45RO and CCR7 expression to identify four CD4⁺ T cell subsets in the peripheral blood of a patient with GPA in remission (right plot) and a HC (left plot). **(B)** Percentages of CD45RO⁻CCR7⁺ (T_{NAIVE}), CD45RO⁺CCR7⁺ (T_{CM}), CD45RO⁺CCR7⁻ (T_{EM}) and CD45RO⁻CCR7⁻ (T_{TD}) subsets within the CD4⁺ T cell population in peripheral blood of patient with GPA in remission (filled squares; *n* = 27) and HCs (open circles; *n* = 16). Horizontal bar represent median percentage. ***P* < 0.01, ****P* < 0.001 vs HCs. GPA: granulomatosis with polyangiitis; HC: healthy control; T_{EM}: CD4⁺ effector memory T cells

percentage of CD4⁺T_{CM} cells did not differ. In addition, the percentage of circulating CD4⁺T_{TD} cells was significantly higher in patients with GPA compared with that in HCs.

To rule out the possibility that the increased proportion of CD4⁺T_{EM} cells was influenced by the current treatment, we compared the proportions of CD4⁺T_{EM} cells between patients with GPA off treatment and patients with GPA receiving immunosuppressive maintenance therapy. No significant differences were found between the treated and untreated patient groups (data not shown).

Increased intracellular pro-inflammatory T cell cytokine production in patients with GPA

Effector T cells produce pro-inflammatory cytokines (such as IL-4, IL-17, IL-21, TNF α and IFN γ) that are presumed to be involved in the disease pathogenesis of GPA. Therefore, we next analysed the pro-inflammatory cytokine profile of CD4⁺ T helper (CD4⁺T_H) cells from patients with GPA and HCs. In all samples, the production of intracellular IL-4, IL-17, IL-21, TNF α and IFN γ was determined in CD4⁺T_H cells by flow cytometry (Fig. 2A). As shown in Fig. 2, the expression of all




Figure 2. Higher percentage of intracellular cytokine production in circulating CD4⁺T_H cells from patients with GPA. Peripheral blood from patients with GPA and HCs was stimulated with PMA and Cal and analysed with flow cytometry for intracellular IL-4, IL-17, IL-21, TNF α and IFN γ cytokine expression. **(A)** Percentages of IL-4⁺, IL-17⁺, IL-21⁺, TNF α ⁺ and IFN γ ⁺ CD4⁺T_H cells from patient with GPA in remission (filled squares; *n* = 27) and HCs (open circles; *n* = 16). **(B)** Percentages of TNF α ⁺IFN γ ⁺, IFN γ ⁺IL-17⁺ and IL-17⁺IL-21⁺ within CD4⁺T_H cells from patient with GPA in remission (filled squares; *n* = 27) and HCs (open circles; *n* = 16). Horizontal bar represent median percentage. **P* < 0.05, ***P* < 0.01, ****P* < 0.001 vs HCs. CD4⁺T_H: CD4⁺ T helper; Cal: calcium ionophore; GPA: granulomatosis with polyangiitis; HC: healthy control; PMA: phorbol myristate acetate

pro-inflammatory cytokines within CD4⁺T_H cells was significantly higher in patients with GPA compared with that in HCs.

Of note, it has become evident that CD4⁺T_H cells may produce additional cytokines in addition to their signature cytokine. For example, T_H1 cells may produce IL-17 in addition to their signature cytokine IFN γ , and T_H17 cells produce IL-21 in addition to their signature cytokine IL-17 [25]. We, therefore, assessed the proportion of CD4⁺T_H cells producing three cytokines (TNF α ⁺IFN γ ⁺, IFN γ ⁺IL-17⁺ and IL-17⁺IL-21⁺). As shown in Fig. 2B, CD4⁺T_H cells from patients with GPA in remission produce significantly higher percentages of TNF α ⁺IFN γ ⁺, IFN γ ⁺IL-17⁺ and IL-17⁺IL-21⁺ cytokines as compared with CD4⁺T_H cells from HCs.

Overall, these results demonstrate the pro-inflammatory nature of the CD4⁺T_H cells in patients with GPA.

ShK-186 reduced the production of cytokines in CD4⁺T_H cells from patients with GPA to the level seen in CD4⁺T_H cells from HCs

Next, we questioned whether the pro-inflammatory cytokine production could be regulated by Kv1.3 channel blockade, using the highly potent Kv1.3 peptide blocker ShK-186. To this end, we stimulated peripheral blood samples of patients with GPA in the presence and absence of ShK-186 and analysed the intracellular cytokine production of IL-4, IL-17, IL-21,

TNF α and IFN γ in CD4⁺T_H cells from patients with GPA (Supplementary Fig. S1, available at *Rheumatology* online). As shown in Fig. 3, addition of ShK-186 to stimulated cell cultures significantly reduced the production of IL-17, IL-21, TNF α and IFN γ in CD4⁺T_H cells from patients with GPA. The effect of ShK-186 on the production of IL-17, IL-21, TNF α and IFN γ was dose dependent (Fig. 3B). Interestingly, the production of IL-17, IL-21, TNF α and IFN γ in CD4⁺T_H cells was normalized to the median cytokine levels detected in HCs. Remarkably, the suppressive effect of ShK-186 on IL-4 production was less pronounced.

In addition, the percentage of CD4⁺T_H cells producing TNF α +IFN γ ⁺, IFN γ +IL-17⁺ and IL-17⁺IL-21⁺ was significantly suppressed by ShK-186 in a dose-dependent manner (Fig. 3C).

It is worth mentioning that the reduction in cytokine production upon pre-treatment with ShK-186 was not attributed to cell death, as ShK-186 does not affect the viability of CD4⁺ T cells (Supplementary Fig. S2, available at *Rheumatology* online).

ShK-186 inhibits cytokine production of CD4⁺ T_{EM} cells

As described previously, CD4⁺T_{EM} cells express significantly higher numbers of Kv1.3 channels on their plasma membrane compared with CD4⁺ T_{NAIVE} cells and CD4⁺T_{CM} cells [17, 26]. Therefore, CD4⁺T_{EM} cells are the most likely target for ShK-186. To study whether Kv1.3 channel blockade by ShK-186 selectively targets cytokine production of CD4⁺T_{EM} cells, we tested the effect of ShK-186 on FACS-sorted CD4⁺T_{NAIVE}, CD4⁺T_{CM}, CD4⁺T_{EM} and CD4⁺T_{TD} cells (Fig. 4A). First, we observed that the pro-inflammatory cytokine production of IL-4, IL-17 and IFN γ after *in vitro* stimulation was significantly increased in CD4⁺T_{EM} cells compared with the other CD4⁺ T cell subsets (CD4⁺T_{NAIVE}, CD4⁺T_{CM} and CD4⁺T_{TD} cells) (Fig. 4). IL-21 was significantly increased in CD4⁺T_{EM} cells compared with CD4⁺T_{NAIVE} and CD4⁺T_{TD} cells, whereas no difference was observed compared with CD4⁺T_{CM} cells. TNF α was produced by all CD4⁺T cell subsets, although the CD4⁺T_{EM} cells showed the highest expression levels of TNF α compared with those of CD4⁺T_{NAIVE}, CD4⁺T_{CM} and CD4⁺ T_{TD} cells. Overall, *in vitro* stimulation with PMA and CaI showed that CD4⁺T_{EM} cells are the major producers of pro-inflammatory cytokines in comparison with other CD4⁺T cell subsets (Fig. 4B). Addition of ShK-186 inhibited CD4⁺T_{EM} cells from producing IL-4, IL-17, TNF α and IFN γ in a dose-dependent manner, whereas the effect was less pronounced in other CD4⁺T_H cell subsets, as their cytokine production remained almost unchanged before and after treatment (Fig. 4B). It is worth mentioning that the production of IL-4 and IL-17 by isolated CD4⁺ T_H subsets other than CD4⁺T_{EM} cells were less pronounced, which could potentially impact the ability of ShK-186 to reduce cytokine production in these subsets. In contrast, the production of IL-21 was slightly affected in both CD4⁺T_{CM} and CD4⁺T_{EM} cells, but reached a significant decrease at a dose of 100 nM in CD4⁺T_{EM} only. It should be noted that a slight reduction was observed in TNF α and IFN γ production in other CD4⁺T_H subsets, mainly CD4⁺T_{CM} cells. This might be expected, as part of T_{CM} cells may develop to T_{EM} cells upon stimulation, and thus express higher levels of Kv1.3 channels that can be targeted by ShK-186.

Interestingly, we observed that TNF α +IFN γ +CD4⁺T_H cells were predominantly present within the CD4⁺T_{EM} subset. Addition of ShK-186 demonstrated a significant dose-dependent inhibition of TNF α +IFN γ ⁺ production by CD4⁺T_{EM} cells compared with the other CD4⁺T cell subsets (Fig. 4B).

Discussion

In the present study, we show that pro-inflammatory cytokine-producing CD4⁺T_H cells are proportionally increased in the circulation of patients with GPA in remission compared with HCs. We found that *in vitro* pharmacological blockade of Kv1.3 channels using ShK-186 decreased the production of pro-inflammatory cytokines, including IL-17, IL-21, TNF α and IFN γ of CD4⁺T_H cells from patients with GPA. Importantly, ShK-186 treatment did not completely inhibit cytokine production but rather reduced the production of these pro-inflammatory cytokines to the level seen in CD4⁺T_H cells from HCs. Furthermore, addition of ShK-186 predominantly affected cytokine production of CD4⁺T_{EM} cells, with minimal effects on cytokine production by other CD4⁺T_H cell subsets (i.e. CD4⁺T_{NAIVE}, CD4⁺T_{CM} and CD4⁺T_{TD} cells).

Our observation that CD4⁺T_H cells from patients with GPA display an increased pro-inflammatory cytokine profile compared with cells from HCs is consistent with previous reports demonstrating increased production of IFN γ and TNF α by peripheral blood mononuclear cells and CD4⁺T_H cells of patients with GPA [11, 27, 28]. In addition, we and others have demonstrated that circulating IL-17- and IL-21-producing CD4⁺T_H cells are significantly increased in patients with GPA, even in remission [13, 14, 29].

Next, we demonstrated that the increase in pro-inflammatory cytokine production in CD4⁺T_H cells from patients with GPA can be prevented by ShK-186 treatment. These data are in line with previous reports showing that ShK-186 preferentially suppresses production of IL-2, IFN γ and TNF α from synovial T cells (mainly consisting of CD4⁺T_{EM} cells) of RA patients [20]. In addition, Chi *et al.* have demonstrated that ShK-186 suppresses cytokine production in human T cells from whole blood [30]. Similar to our observations, these authors reported that Shk-186 was most effective in suppressing the production of IL-2, followed by IFN γ and IL-17, but had a minor effect only on IL-4 production. Interestingly, it has been shown that T cell receptor (TCR)-induced Ca²⁺ signalling is lower in T_H2 cells than in T_H1, T_H17 or naïve T cells, suggesting that Kv1.3-mediated T cell activation is differently regulated not only in T cell subsets (i.e. T_{NAIVE}, T_{CM} and T_{EM}) but also between different T cell phenotypes [31, 32]. This could explain the fact that blocking Kv1.3 channels using ShK-186 has a more pronounced effect on the pro-inflammatory cytokines IFN γ and IL-17 compared with IL-4.

In addition to its effect on T cells, we have previously explored the anti-inflammatory effect of ShK-186 on B cells. We found that ShK-186 modulates the effector functions of B cells of patients with GPA *in vitro* by reducing the production of ANCAs and pro-inflammatory cytokines [33]. Thus, utilizing a Kv1.3-based therapy in GPA would represent a significant improvement over existing therapies. In addition, ShK-186 may also be beneficial in the treatment of COVID-19, as it




Figure 3. Dose-dependent suppression of pro-inflammatory cytokines by ShK-186 in CD4⁺T_H cells from patients with GPA. Peripheral blood from patients with GPA and HCs was stimulated with PMA and Cal with and without increasing concentrations of ShK-186. Intracellular IL-4, IL-17, IL-21, TNF α and IFN γ cytokine production in CD4⁺T_H cells was analysed using flow cytometry. **(A)** Representative flow cytometry dot plots of cytokine expression within CD4⁺T_H cells after stimulation in the presence (lower panels) and absence (upper panels) of ShK-186 from a patient with GPA in remission. **(B)** Percentages of cytokine-producing CD4⁺T_H cells after stimulation in the presence and absence of ShK-186 from patients with GPA in remission (grey box and whiskers; *n* = 27). **(C)** Percentages of TNF α ⁺IFN γ ⁺, IFN γ ⁺IL-17⁺ and IL-17⁺IL-21⁺ within CD4⁺T_H cells after stimulation in the presence and absence of ShK-186 from patients with GPA in remission (grey box and whiskers; *n* = 27). Box-and-whiskers plots (tukey): boxes represent median values and interquartile range. Red horizontal dashed line represents median percentage of cytokine production by CD4⁺T_H cells from HCs. **P* < 0.05, ***P* < 0.01, ****P* < 0.001 vs stimulated CD4⁺T_H cells without ShK-186. CD4⁺T_H: CD4⁺T helper; Cal: calcium ionophore; GPA: granulomatosis with polyangiitis; HC: healthy control; phorbol myristate acetate




Figure 4. ShK-186 inhibits the pro-inflammatory cytokine production of CD4⁺T_{EM} cells. CD4⁺T cells subsets (i.e. CD4⁺T_{NAIVE}, CD4⁺T_{CM}, CD4⁺T_{EM} and CD4⁺T_{TD} cells) were isolated from peripheral blood mononuclear cells of HCs followed by stimulation with PMA and Cal with and without increasing concentrations of ShK-186. Intracellular IL-4, IL-17, IL-21, TNF α and IFN γ cytokine production in the CD4⁺T cell subsets was analysed using flow cytometry. **(A)** Representative flow cytometry dot plots of CD4⁺T cells subsets based on surface expression of CD45RO and CCR7 (centre dot plot), and the cytokine expression within CD4⁺T_{NAIVE} cells (upper left, red), CD4⁺T_{CM} cells (upper right, green), CD4⁺T_{TD} cells (lower left, purple) and CD4⁺T_{EM} cells (lower right, blue) after stimulation in the presence and absence of ShK-186 from a HC. **(B)** Percentages of intracellular cytokine production in CD4⁺T_{NAIVE} cells (red symbol and line), CD4⁺T_{CM} cells (green symbol and line), CD4⁺T_{TD} (purple symbol and line) and CD4⁺T_{EM} cells (blue symbol and line) after stimulation in the presence and absence of ShK-186 from HCs ($n = 5$). Data represent mean values \pm SEM. ## $P < 0.01$ and ### $P < 0.001$ indicate CD4⁺T_{EM} cells vs CD4⁺T_{NAIVE} cells, CD4⁺T_{CM} cells and CD4⁺T_{TD} cells. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ indicate CD4⁺T_{EM} cells with vs without ShK-186. ##: IL-21 production in CD4⁺T_{EM} cells is only significantly different compared with CD4⁺T_{NAIVE} and CD4⁺T_{TD} cells and not significantly different compared with CD4⁺T_{CM} cells. GPA: granulomatosis with polyangiitis; HC: healthy control; PMA: phorbol myristate acetate; Cal: calcium ionophore; CD4⁺T_{CM}: CD4⁺ central memory T cells; CD4⁺T_{EM}: CD4⁺ effector memory T cells; CD4⁺T_{NAIVE}: CD4⁺ naive T cells; CD4⁺T_{TD}: CD4⁺ terminal differentiated T cells

has the potential to mitigate the production of pro-inflammatory cytokines and thus suppresses the cytokine storms occurring in COVID-19 patients [34].

Using sorted CD4⁺T cell subsets, we observed that cytokine production is most effectively suppressed by ShK-186 in CD4⁺T_{EM} cells. This can be explained by the fact that activation of T cells has differential effects on the expression of potassium channels in different T cells subsets. CD4⁺T_{NAIVE} and CD4⁺T_{CM} cells preferentially upregulate the Ca²⁺-activated potassium KCa3.1 channel, while CD4⁺T_{EM} cells preferentially increase their Kv1.3 expression [17]. This switch in channel expression significantly affects the responsiveness of T cell subsets to Kv1.3 and KCa3.1 blockers, CD4⁺T_{EM} cells being highly sensitive to Kv1.3 channel blockers and CD4⁺T_{NAIVE}/T_{CM} cells being more sensitive to KCa3.1 channel blockers.

In addition, ShK analogues have shown similar effects on rat T cells in various immune-mediated inflammatory disease models. In these studies, ShK analogues showed efficacy in preventing and ameliorating acute experimental autoimmune encephalomyelitis (EAE, a model of multiple sclerosis) and pristane-induced arthritis in rats [20, 35]. Moreover, in a rat model of anti-GBM GN, the majority of CD4⁺T cells infiltrating the kidney were Kv1.3^{high} T_{EM} cells [36]. Rats treated with a Kv1.3 blocker developed less proteinuria and had fewer crescentic glomeruli than rats treated with placebo. ShK-186 may therefore be useful in the treatment of autoimmune kidney disease like GPA.

In addition to the ShK-186, several other types of Kv1.3 blockers have been developed and studied. For instance, ShK-related peptides derived from parasitic worms, such as AcK1 and BmK1, have been shown to block Kv1.3 channels and suppress T_{EM} cell responses *in vitro* and *in vivo* [37]. Other scorpion venom-derived peptides, including HsTX1 and Imk, have been also identified as potent Kv1.3 channel blockers, and have demonstrated effectiveness in controlling arthritis and reducing the severity of experimental autoimmune encephalomyelitis, respectively [38, 39]. Additionally, Vm24, a peptide derived from the scorpion venom, has shown high selectivity and potency in blocking Kv1.3 channels and impairing the synthesis and secretion of Th-cell cytokines in response to TCR engagement [40]. These Kv1.3 blockers are currently being investigated as potential therapeutic agents for autoimmune diseases.

Compared with other Kv1.3 blockers, ShK-186 has several advantages. One of the key advantages of ShK-186 over other Kv1.3 blockers is its high selectivity. It has been shown to be >100-fold more selective for Kv1.3 compared with other potassium channels [19]. Another unique aspect of ShK-186 is its tight binding to the Kv1.3 channels and long duration of action, which may allow for less frequent dosing. The unique pharmacokinetic profile of ShK-186 may make it a promising therapeutic option for the treatment of autoimmune diseases.

It is worth noting that in addition to CD4⁺T_{EM} cells, Kv1.3 channels are also expressed in various tissues in the body, including the kidney, liver and the CNS. Therefore, one may argue that toxic side effects are a potential concern when using Kv1.3 channel blockers. However, Kv1.3 blockers (especially the ShK analogues) have been shown to have an excellent safety profile in animal models [19, 20, 41]. ShK-186 was reported to exhibit no perceptible *in vitro* toxicity, was negative in the Ames test, and had no effect on cardiac parameters

[19]. Furthermore, repeated subcutaneous administration of ShK-186 in rats did not cause clinical toxicity, as evidenced by normal blood cell counts and serum chemistry parameters, and no signs of histopathological changes in various tissues [19, 20]. Moreover, *in vivo* studies have demonstrated that the efficacy of ShK186 can be achieved without general immunosuppression [41]. In rats, administration of ShK-186 did not compromise the protective immune response to acute viral (influenza) or bacterial (*Chlamydia*) infections at pharmacological doses that did ameliorate autoimmune diseases [41]. Importantly, ShK-186 has completed phase 1 b trial in psoriasis patients, showing the blocker is well tolerated and improves psoriatic skin lesions by inhibiting T cell mediators of inflammation [42].

Therapies targeting CD4⁺T_{EM} cells via blocking Kv1.3 channels may have an advantage over current therapies in GPA, because CD4⁺T_{NAIVE} and CD4⁺T_{CM} would escape the inhibition by ShK-186. Leaving T_{NAIVE} and T_{CM} CD4⁺T cells unimpaired, patients with GPA treated with ShK-186 would therefore be able to preserve protective immune responses against most pathogenic challenges. On the other hand, a potential disadvantage of Kv1.3 blockade is that it likely suppresses all CD4⁺T_{EM} cells, thereby affecting immune responses against chronic infections. However, as demonstrated here, it may be possible to titrate ShK-186 to a dose at which it normalizes, but does not completely suppress, CD4⁺T_{EM} cell responses. Moreover, the Kv1.3 blocker is reversible, and therapy could be paused in the event of an acute infection, unlike current treatments in GPA (i.e. CYC, high-dose CSs and rituximab), which take several months to subside.

In this study, blood samples from patients with GPA in remission were evaluated for the effect of ShK-186, rather than blood samples from those with active disease. We have previously shown that during active disease CD4⁺T_{EM} cells appear to migrate towards inflamed tissues [12]. Analysis of the effect of ShK-186 on circulating CD4⁺T_H cells in patients with GPA with active disease will exclude cells that have migrated to inflamed tissue, which are (probably) the most relevant cells. Therefore, studying samples from patients in remission seems more relevant for this analysis. However, it should be noted that our findings may not fully reflect the effect of ShK-186 on T_{EM} cells during disease progression, and therefore future studies should aim to include samples from patients with active disease to better understand the potency of ShK-186 on CD4⁺ T_{EM} cells in various stages of the disease. Future *in vivo* studies should also consider the impact of ShK-186 on PR3-specific T cells and its impact on protective immunity.

In conclusion, the data presented here demonstrate that the Kv1.3 blocker ShK-186 suppresses pro-inflammatory cytokine production in CD4⁺T_H cells from patients with GPA, and predominantly affects the cytokine production of CD4⁺T_{EM} cells. Importantly, ShK-186 treatment reduced the production of the pro-inflammatory cytokines to the level seen in CD4⁺T_H cells from HCs. These findings support the potential of selective Kv1.3 blockade as a therapeutic strategy for patients with GPA.

Supplementary material

Supplementary material is available at *Rheumatology* online.

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

Contribution statement

All authors contributed to the concept and design. L.L. performed the experiments, statistical analysis, drafted the manuscript, and contributed to interpretation of the data. W.A. and P.H. contributed to interpretation of the data and critically revised the manuscript. A.R. and C.S. contributed to inclusion of patients with GPA, and assessed and participated in the interpretation of clinical data, and critical revision of the manuscript. E.M.-E., E.T. and S.I. critically revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the Dutch Arthritis foundation (Reumafonds project number 12–2-407).

Disclosure statement: The authors have declared no conflicts of interest.

References

- Hilhorst M, van Paassen P, Tervaert JWC. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. *J Am Soc Nephrol* 2015;26:2314–27.
- Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. *Nat Rev Rheumatol* 2014;10:463–73.
- Biedroń G, Włodarczyk A, Wawrzycka-Adamczyk K *et al.* Treatment and its side effects in ANCA-associated vasculitides – study based on POLVAS registry data. *Adv Med Sci* 2020;65:156–62.
- Jain K, Jawa P, Derebail VK, Falk RJ. Treatment updates in antineutrophil cytoplasmic autoantibodies (ANCA) vasculitis. *Kidney360* 2021;2:763–70.
- Schönermarck U, Gross WL, de Groot K. Treatment of ANCA-associated vasculitis. *Nat Rev Nephrol* 2014;10:25–36.
- Stone JH, Merkel PA, Spiera R *et al.*; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *New Engl J Med* 2010;363:221–32.
- Guilpain P, le Bihan C, Foulongne V *et al.* Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. *Ann Rheum Dis* 2021;80:e10.
- Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. *Ann Rheum Dis* 2021;80:e67.
- Deepak P, Kim W, Paley MA *et al.* Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2. *Ann Intern Med* 2021;174:1572–85.
- Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CGM. Persistent expansion of CD4⁺ effector memory T cells in Wegener's granulomatosis. *Kidney Int* 2006;70:938–47.
- Komocsi A, Lamprecht P, Csernok E *et al.* Peripheral blood and granuloma CD4⁺CD28⁻ T cells are a major source of interferon- γ and tumor necrosis factor- α in Wegener's granulomatosis. *Am J Pathol* 2002;160:1717–24.
- Abdulahad WH, Kallenberg CGM, Limburg PC, Stegeman CA. Urinary CD4⁺ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2009;60:2830–8.
- Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CGM. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. *Arthritis Rheum* 2008;58:2196–205.
- Abdulahad WH, Lapse N, Stegeman CA *et al.* Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA). *Arthritis Res Ther* 2013;15:R70.
- Lintermans LL, Stegeman CA, Heeringa P, Abdulahad WH. T cells in vascular inflammatory diseases. *Front Immunol* 2014;5:504.
- Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. *Immunol Rev* 2009;231:59–87.
- Wulff H, Calabresi PA, Allie R *et al.* The voltage-gated Kv1.3 K⁺ channel in effector memory T cells as new target for MS. *J Clin Invest* 2003;111:1703–13.
- Beeton C, Barbaria J, Giraud P *et al.* Selective blocking of voltage-gated K⁺ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. *J Immunol* 2001;166:936–44.
- Beeton C, Pennington MW, Wulff H *et al.* Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. *Mol Pharmacol* 2005;67:1369–81.
- Beeton C, Wulff H, Standifer NE *et al.* Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. *Proc Natl Acad Sci USA* 2006;103:17414–9.
- Tarcha EJ, Chi V, Muñoz-Eliás EJ *et al.* Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. *J Pharmacol Exp Ther* 2012;342:642–53.
- Jennette JC, Falk RJ, Bacon PA *et al.* 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013;65:1–11.
- Leavitt RY, Fauci AS, Bloch DA *et al.* The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. *Arthritis Rheum* 1990;33:1101–7.
- Luqmani RA, Bacon PA, Moots RJ *et al.* Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. 1994;87:671–8.
- Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Defining the human T helper 17 cell phenotype. *Trends Immunol* 2012;33:505–12.
- Chandy KG, Wulff H, Beeton C *et al.* K⁺ channels as targets for specific immunomodulation. *Trends Pharmacol Sci* 2004;25:280–9.
- Lüdviksson BR, Sneller MC, Chua KS *et al.* Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. *J Immunol* 1998;160:3602–9.
- Csernok E, Trabandt A, Müller A *et al.* Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. *Arthritis Rheum* 1999;42:742–50.
- Nogueira E, Hamour S, Sawant D *et al.* Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. *Nephrol Dial Transplant* 2010;25:2209–17.
- Chi V, Pennington MW, Norton RS *et al.* Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. *Toxicon* 2012;59:529–46.
- Sloan-Lancaster J, Steinberg TH, Allen PM. Selective loss of the calcium ion signaling pathway in T cells maturing toward a T helper 2 phenotype. *J Immunol* 1997;159:1160–8.
- Weber KS, Miller MJ, Allen PM. Th17 cells exhibit a distinct calcium profile from Th1 and Th2 cells and have Th1-like motility and NF-AT nuclear localization. *J Immunol* 2008;180:1442–50.
- Land J, Lintermans LL, Stegeman CA *et al.* Kv1.3 channel blockade modulates the effector function of B cells in granulomatosis with polyangiitis. *Front Immunol* 2017;8:1205.

34. Kazama I. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: can it be a novel therapeutic strategy? *Drug Discov Ther* 2020;14:143–4.
35. Beeton C, Wulff H, Barbaria J *et al.* Selective blockade of T lymphocyte K⁺ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. *Proc Natl Acad Sci USA* 2001;98:13942–7.
36. Hyodo T, Oda T, Kikuchi Y *et al.* Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. *Am J Physiol Renal Physiol* 2010;299:F1258–69.
37. Chhabra S, Chang SC, Nguyen HM *et al.* Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. *FASEB J* 2014;28:3952–64.
38. Tanner MR, Tajhya RB, Huq R *et al.* Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog. *Clin Immunol* 2017;180:45–57.
39. Yuan XL, Zhao YP, Huang J *et al.* A Kv1.3 channel-specific blocker alleviates neurological impairment through inhibiting T-cell activation in experimental autoimmune encephalomyelitis. *CNS Neurosci Ther* 2018;24:967–77.
40. Veytia-Bucheli JI, Jiménez-Vargas JM, Melchy-Pérez EI *et al.* Kv1.3 channel blockade with the Vm24 scorpion toxin attenuates the CD4⁺ effector memory T cell response to TCR stimulation. *Cell Commun Signal* 2018;16:45.
41. Matheu MP, Beeton C, Garcia A *et al.* Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. *Immunity* 2008;29:602–14.
42. Tarcha EJ, Olsen CM, Probst P *et al.* Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: a randomized phase 1b trial. *PLoS One* 2017;12:e0180762.